Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast ...

Despite a slight revenue dip, Icon PLC (ICLR) showcases resilience with strong bookings and strategic investments in digital ...

ICON's fourth-quarter 2024 earnings and revenues beat estimates as it manages to navigate a challenging transition period. Key Insights ICON's estimated fair value is US$345 based on 2 Stage Free ...

Icon PLC (ICLR) delivered earnings and revenue surprises of 0.29% and 0.29%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Icon PLC (ICLR) on Wednesday reported fourth-quarter earnings of $260 million. On a per-share basis, the Dublin 18, Ireland-based company said it had profit of $3.16. Earnings, adjusted for one-time ...

ICON's fourth-quarter 2024 earnings and revenues beat estimates as it manages to navigate a challenging transition period.